<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - NAMSW (NAMSW)</title>
    <description>Latest news, press releases, and SEC filings for NAMSW (NAMSW)</description>
    <link>https://caymanjournal.com/stock/NAMSW</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 21:31:33 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/NAMSW/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>PRE 14A — NewAmsterdam Pharma Co N.V.</title>
      <description># 📜 What This Document Is 📄
This document is a Preliminary Proxy Statement (PRE 14A). Think of it as the comprehensive instruction manual for the company&apos;s upcoming annual shareholder meeting. It&apos;s *not* an earnings report; instead, it outlines what the company is asking you, the shareholder, to v</description>
      <link>https://caymanjournal.com/stock/NAMSW/sec-filing/0001193125-26-162757</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/NAMSW/sec-filing/0001193125-26-162757</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>